Will AI innovations at the 2025 Veeva Summit change the long-term growth story for Veeva Systems (VEEV)?

• Earlier this month, Veeva Systems held the 2025 Veeva Commercial Summit in Spain, featuring presentations by senior leaders from its product, consulting, and AI teams on the company’s latest innovations and solutions for life sciences customers.
• The conference highlighted Veeva’s continued investment in AI-driven cloud products and deepening engagement with European and global pharmaceutical customers, highlighting its role as a technology partner in the digitalization of healthcare.
• Given the summit’s focus on AI integration and commercial product updates, we explore how these developments could impact Veeva’s long-term growth story.

Find companies that have promising cash flow potential but are trading below their fair value.

Veeva Systems Investment Story Summary

To become a Veeva Systems shareholder, you need to believe in the company’s ability to stay at the forefront of digital transformation in life sciences, especially through its AI-powered cloud solutions and growing international customer adoption. The Commercial Summit in Spain focused attention on further AI integration, but it did not significantly change the pending third-quarter earnings driver, a near-term revenue driver, nor did it allay concerns about increased competition from tech giants, which remains the biggest short-term risk to watch.

Among the latest updates, Veeva’s announcement that Gilead Sciences is working to adopt Vault CRM that leverages AI agents for commercial execution stands out given recent conference themes on automation and advanced analytics. These advancements with major customers are directly tied to the theory that corporate relationships and growing market share in the pharmaceutical industry can help drive recurring revenue and improve revenue visibility.

However, investors should also be aware of the growing threat from powerful competitors expanding their services into the healthcare sector.

Read the full story on Veeva Systems (it’s free!)

The Veeva Systems story projects $4.3 billion in revenue and $1.3 billion in revenue by 2028. This would require a 12.8% annual revenue increase, or an increase in revenue of $809.9 million to $490 million.

Find out how Veeva Systems’ projections resulted in a fair value of $320.62, 9% above the current price.

explore other perspectives

Seven members of the Simply Wall St Community estimate Veeva’s fair value to be between US$230 and US$320.62. While views differ, many see risks from increased competition as having far-reaching implications for future profitability and growth, so we’re looking for alternative perspectives and seeing where our own analysis fits.

Check out 7 other fair value estimates for Veeva Systems – Find out why the stock is worth 22% less than its current price.

Build your own Veeva system story

Don’t agree with an existing story? Create your own in under 3 minutes. Following the herd rarely yields exceptional investment returns.

• A great starting point for Veeva Systems research is an analysis that reveals two key benefits that can influence your investment decision.
• Our free Veeva Systems research report provides comprehensive fundamental analysis compiled into a single visual (snowflake) that allows you to easily assess Veeva Systems’ overall financial health at a glance.

Interested in other possibilities?

These stocks are on the move – our analysis flagged them today. Act fast before prices catch up.

This article by Simply Wall St is general in nature. We provide commentary using only unbiased methodologies, based on historical data and analyst forecasts, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.

Do you have feedback on this article? Interested in its content? Please contact us directly. Alternatively, email editorial-team@simplywallst.com.